Trial Profile
Phase I/II trial of IMO-2055 with an intratumoral administration approach in combination with checkpoint kinase inhibitors in cancer patients
Status:
Planning
Phase of Trial:
Phase I/II
Latest Information Update: 13 Feb 2023
Price :
$35
*
At a glance
- Drugs IMO 2055 (Primary) ; Checkpoint kinase inhibitors
- Indications Cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Aceragen; Idera Pharmaceuticals
- 17 Jan 2023 According to an Aceragen media release, Idera Pharmaceuticals has changed its name to Aceragen.
- 27 Mar 2015 New trial record
- 12 Mar 2015 According to an Idera Pharmaceutical media release, data for at least one of the two phase I/II trials is expected to be available by end of 2016.